314 results
8-K
EX-99.1
ORKA
Oruka Therapeutics Inc.
14 Nov 24
Report of Independent Registered Public Accounting Firm
4:56pm
initiation fee of $0.8 million was due to Paragon. This amount was recognized as a research and development expense during the period ended March 31 … to ORKA-002 incurred by Paragon between January 1, 2024 and March 6, 2024. This amount was recognized as a research and development expenses during
8-K
EX-99.1
ORKA
Oruka Therapeutics Inc.
13 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
4:02pm
financing for research and development, general corporate expenses, and working capital needs. The Company expects that its cash will fund its operating plan
8-K
EX-99.4
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
if and as it: continues its research and development and discovery-related development of its programs, ORKA-001, ORKA-002, and ORKA-003; submits for and receives … and initiates discovery-related activities and preclinical studies for those programs; hires additional research and development and clinical personnel
8-K
EX-99.3
zgfvr447fartkgn6v5x
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-99.5
2vny0
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
1fyt02
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-99.2
1izelafd
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-10.25
d81cmy ojmq
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
425
EX-99.1
7wufv0 ss
26 Aug 24
Business combination disclosure
7:53pm
425
5hsc0absne
26 Aug 24
Business combination disclosure
7:53pm
8-K
EX-99.1
g8yxfpltqxojsmf2
26 Aug 24
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
7:51pm
8-K
jl244bsx8iqluruzkmq
26 Aug 24
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
7:51pm
8-K
EX-99.1
p9mjxxyzthp tam
23 Aug 24
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
4:35pm
8-K
nvrj3gkqn6
23 Aug 24
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
4:35pm
425
wvegk8 ik
16 Aug 24
Business combination disclosure
4:27pm
425
EX-99.1
wmntegmav9l6ggzgi
16 Aug 24
Business combination disclosure
4:27pm
8-K
nsb68
16 Aug 24
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
4:25pm
8-K
EX-99.1
g2fwktz6 b0iutv
16 Aug 24
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
4:25pm